

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT3973350

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
FLUORINOV PHARMA INC.	07/20/2016
RECEIVING PARTY DATA	
Name:	TRILLIUM THERAPEUTICS INC.
Street Address:	2488 DUNWIN DRIVE
City:	MISSISSAUGA
State/Country:	CANADA
Postal Code:	L5L 1J9
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	14420817
CORRESPONDENCE DATA	
Fax Number:	(416)361-1398
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	416-364-7311
Email:	pfolkins@bereskinparr.com
Correspondent Name:	BERESKIN & PARR LLP/S.E.N.C.R.L., S.R.L.
Address Line 1:	40 KING STREET WEST, 40TH FLOOR
Address Line 4:	TORONTO, CANADA M5H 3Y2
ATTORNEY DOCKET NUMBER:	9579-P39205US02
NAME OF SUBMITTER:	PATRICIA FOLKINS
SIGNATURE:	/Patricia Folkins/
DATE SIGNED:	07/22/2016
Total Attachments: 4	
source=Assignment_Trillium#page1.tif	
source=Assignment_Trillium#page2.tif	
source=Assignment_Trillium#page3.tif	
source=Assignment_Trillium#page4.tif	

ASSIGNMENT

WHEREAS **FLUORINOV PHARMA INC.**, whose full post office address is **2488 Dunwin Drive, Mississauga, Ontario, Canada, L5L 1J9**, (hereinafter the "Assignor") is the owner of an invention disclosed in the patent applications listed in the attached Schedule A (hereinafter the "Applications").

AND WHEREAS, **TRILLIUM THERAPEUTICS INC.** whose full post office address is **2488 Dunwin Drive, Mississauga, Ontario, Canada, L5L 1J9**, (hereinafter "the Assignee"), has acquired from the Assignor, the Assignor's entire right, title and interest in and to the invention, in all countries of the world, including the Assignor's rights to the Applications, and all related applications thereon, including any and all, international, national and regional phase applications based on the Applications, and other counterpart applications in all countries, and any and all substitutes, divisionals, continuations and continuations-in-part, and any Letters Patent that may be obtained therefor, and in any and all reissues, extensions, renewals and reexaminations of such applications and patents;

In consideration of the sum of One Dollar (\$1.00) and other good and valuable consideration, the receipt and sufficiency of all of which is hereby acknowledged, the Assignor confirms that it has sold and does hereby sell and assign, transfer and set over to the Assignee, all of the Assignor's right, title and interest for Canada, the United States of America, its territories, dependencies and possessions, and for all other countries in the world, in and to the invention, including the Assignor's rights to the Applications, and all related applications and patents thereon, to be held and enjoyed by the Assignee, its assigns and successors, as fully and entirely as the same would have been held and enjoyed by the Assignor, had this Assignment not been made.

The Assignor shall without further consideration do all such things and execute all such documents as may be necessary or desirable to obtain and maintain the Applications for the invention, and all related applications and patents thereon, in any and all countries, and to vest title thereto in the Assignee, its successors, assigns and legal representatives or nominees.

The Assignor authorizes and empowers the Assignee, its successors, assigns and legal representatives or nominees, to invoke and claim for any of the Applications, and all related applications and patents thereon, filed by the Assignor or the Assignee, the benefit of the right of priority provided by the International Convention for the Protection of Industrial Property, as amended, or by any convention which may henceforth be substituted for it, and to invoke and claim such right of priority without further written or oral authorization from the Assignor.

The Assignor authorizes and empower Bereskin & Parr LLP/S.E.N.C.R.L., s.r.l., whose complete address is Scotia Plaza, 40 King Street West, 40th Floor, Toronto, Ontario M5H 3Y2 to insert on this Assignment any further identification, to prepare any translation which may be necessary or desirable in order to comply with the rules for recordation of this document in any country and to correct any clerical error in this assignment.


The Commissioner of Patents & Trademarks is hereby authorized and requested to issue any Letters Patent for the Applications, and all related applications thereon, to the Assignee, for its sole use and benefit; and for the use and benefit of its successors and assigns, to the full end of the term for which Letters Patent may be granted, as fully and entirely as the same would have been held by the Assignor had this Assignment and sale not been made.

If a provision of this Assignment is or becomes illegal, invalid or unenforceable in any jurisdiction, that shall not affect the validity or enforceability in that jurisdiction of any other provision of this Assignment, or the validity or enforceability in other jurisdictions of that or any other provision of this Assignment.


The Assignor hereby acknowledges that any willful false statement made in this assignment/declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

The Parties confirm their express wish that this Assignment be drawn up in the English language. *Les parties confirment leur volonté expresse que cette cession soit rédigée en langue anglaise.*

SIGNED AT Mississauga, Ontario, this 20th day of July, 2016.




Witness




FLUORINOV PHARMA INC.
Name: Malika Hashi
Title: Vice President

SIGNED AT Mississauga, Ontario, this 20th day of July, 2016.



Witness



TRILLIUM THERAPEUTICS INC.
Name: Niclas Stenholm
Title: President & CEO

Schedule A

B&P No.	Title	Application No.	Country	Filing Date
9579- P39205AU00	FLUORINATED EPOXYKEYTONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS	2013302269	Australia	August 13, 2013
9579- P39205CA00	FLUORINATED EPOXYKEYTONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS	2881999	Canada	August 13, 2013
9579- P39205CN00	FLUORINATED EPOXYKEYTONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS	201380053443.0	China	August 13, 2013
9579- P39205EP00	FLUORINATED EPOXYKEYTONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS	13829194.3	Europe	August 13, 2013
9579- P39205HK00	FLUORINATED EPOXYKEYTONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS	15112672.3	Hong Kong	August 13, 2013
9579- P39205PC00	FLUORINATED EPOXYKEYTONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS	PCT/CA2013/050620	PCT	August 13, 2013
9579- P39205US01	NOVEL FLUORINATED PROTEASOME INHIBITORS FOR TREATING CANCERS AND OTHER HUMAN DISORDERS	61/682,836	United States	August 14, 2012
9579- P39205US02	FLUORINATED EPOXYKEYTONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS	14/420,817	United States	February 10, 2015